S
urgical bypass grafting is the essential treatment for lower extremity arterial occlusive disease, with ≈80 000 vein graft bypass operations occurring each year. 1 Despite its widespread use, lower extremity revascularization still suffers from fairly modest outcomes, with 5-year graft patency rates of 50% to 70%. 2 Aspirin and other antiplatelets have reduced the incidence of acute graft thrombosis, 3 but the vast majority of graft failures are because of the chronic processes of intimal hyperplasia and subsequent graft atherosclerosis. 4, 5 Both exposure of the newly implanted vein to arterial hemodynamics and the vascular trauma sustained during the operation are thought to induce a critical response from the host's immune system, which, in large part, drives the process of vein graft remodeling. 5, 6 Although the association between circulating markers of systemic inflammation, such as CRP (C-reactive protein), and postimplantation graft events in humans have been described in the literature, 7 less is known about the influence of cell-mediated immunity after vein bypass operations. Animal models have demonstrated that monocytes, a cell type central to the innate immune system, are known to play a particularly critical role in the vessel's response to injury. 8, 9 In particular, early monocyte recruitment into the vein graft wall, mediated by inflammasome activation within injured vascular smooth muscle cells, has been identified as a critical driver of the hyperplastic response. [10] [11] [12] Despite this mounting evidence in small animal models, the potential contribution of monocyte biology to human vein bypass graft failure has not been explored.
In the current study, we hypothesized that the early response pattern of circulating monocytes would be an important determinant of long-term vein graft success or failure. Specifically, we sought to identify key elements within the monocyte genome that could be selectively targeted to manipulate monocyte activity and, consequently, graft outcome. By exploring the evolution of the human monocyte transcriptome throughout the first month directly after infrainguinal vein graft implantation, we identify a core set of genes that are associated with graft failure. Using Bayesian network analysis and a series of regression models to describe interactions among these key monocyte regulatory genes, a predictive model describing the downstream effects of their manipulations on graft outcome is developed. Ultimately, through a combination of high-throughput genomics, gene pathway analysis, and probabilistic network modeling, we identify specific monocyte genes whose alterations may result in improved vein graft patency in human patients.
METHODS
The data that support the findings of this study are available from the corresponding author on reasonable request.
Patient Selection and Outcome Measures
Patients undergoing autogenous infrainguinal vein bypass grafting for critical limb ischemia or disabling claudication between 2007 and 2012 at either the UF Health Shands Hospital or the Malcom Randall Veterans Affairs Medical Center were candidates for enrollment in this prospective study. All patients provided informed consent before participation. The project was approved by the Institutional Review Board at the University of Florida and the Research and Development Committee at Malcom Randall Veterans Affairs Medical Center.
Infrainguinal vein bypass grafting was performed in a standard fashion, using nonreversed ipsilateral long saphenous vein whenever possible. All patients were placed on aspirin; those with composite vein conduit or disadvantaged arterial outflow were placed on warfarin. Postoperatively, the subjects underwent duplex ultrasound, ankle-brachial indices, and physical examination at 1 week and 1, 3, 6, and 12 months to monitor graft patency. Grafts that occluded, required reintervention, or showed evidence of stenosis
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(>3.5-fold peak systolic velocity increase across the segment and a >70% stenosis on subtraction angiography) within the first postoperative year were considered failures. Grafts demonstrating stenosis or requiring reintervention within 1 week of surgery were considered technical failures and excluded from the analysis.
Means comparisons of demographic and procedural variables were performed with SPSS software (version 22; Chicago, IL). Either Pearson χ 2 or Fisher exact test was used for categorical variables, and Student t test was used for continuous variables. P<0.05 was the criterion for null hypothesis rejection.
Sample Collection, Monocyte RNA Isolation, and Microarray Hybridization
Fifteen milliliters of whole blood were collected in EDTA directly before the operation and then at 1, 7, and 28 days post-operation. Monocytes were isolated by negative selection, evaluated for surface marker phenotype using flow cytometry, and prepared for RNA isolation as described in the Supplemental Methods and Results sections. cDNA was generated using Ovation Pico WT kit (NuGEN, San Carlos, CA) and labeled using GeneChip WT Terminal Labeling (Affymetrix, Santa Clara, CA). Samples were hybridized to either a proprietary Glue Grant Human Transcriptome Array (GGH2; Affymetrix) or standard Human GeneChip (GGH3; Affymetrix). 13 The raw expression data were normalized and transformed with Partek Genomics Suite (Partek, St. Louis, MO).
Microarray Gene Expression and Genomic Analysis
BRB-Array Tools (National Institutes of Health, Biometric Research Branch) linear mixed-effects modeling was used to evaluate the interrelationship of time and outcome on regulator gene expression, with time and outcome modeled as fixed factors and patient treated as a random factor such that:
where i=patient index, j=graft outcome, k=time index, and e is the residual error term.
Hierarchical clustering and unsupervised heat map creation were performed using dChip software (Harvard, Boston, MA). Principal component analysis, which illustrates cumulative gene expression relationships among time points and between outcome groups, was performed with Partek Software and Matlab. Distance from reference (DFR) scores were used to quantitatively compare the gene expression deflection from the entire baseline group between successful and failed grafts, using the equation:
where e i is the patient's gene expression level and M i and V i are the whole group mean and variance for the i th probe set.
14 Split-plot ANOVA tested the interaction between time and outcome (or severity) group for distance from reference scores. A previously described custom clustering algorithm grouped together genes with similar expression profiles over time to identify those clusters most likely to be associated with vein graft outcome. 15 Briefly, gene expression levels over time were modeled using a nonparametric approach based on Legendre orthogonal polynomials. The optimal number of gene clusters and Legendre orthogonal polynomial order were determined by plotting Bayesian information criterion values for various numbers of gene clusters at several Legendre orthogonal polynomial orders. The combination of gene cluster number and Legendre orthogonal polynomial order that offer the best curve fitting was selected for modeling. By calculating the posterior probabilities of each gene belonging to each cluster, the most likely cluster to which each gene belongs was determined.
Two-way ANOVA, minimum normalized effect size, and expression fold change criteria were used to identify those pathways most highly associated with the outcome variable. Pathway and gene ontology analyses, as well as identification of important upstream regulatory genes, 16 were performed with Ingenuity Pathway Analysis software (QIAGEN Silicon Valley, Redwood, CA).
Time-Dependent Gene Expression Kinetics
Expression data for the 64 genes contained within the 3 final clusters were fit to the following exponential function to model the maximum expression and decay time constants (Matlab, version R2014b; MathWorks, Natick, MA).
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where E(t)=gene expression at time point t; E max =the patient's maximum value of postoperative gene expression; t max =the time point at which the patient's maximum value of gene expression occurs; and ΔT is the time constant of decay.
Interrelationship Among Upstream Regulator Genes and a Gene-Based Model to Predict Graft Phenotype
Gene expression data for the 8 upstream regulator genes were discretized as 1 (downregulation) or 2 (upregulation) by comparing with the baseline expression level. A Bayesian network was created to describe the quantitative relationships among these genes, as described in the Methods section.
A model to predict the directional change in mediator gene expression that would result from silencing of a specific upstream regulator gene was created. Using those interactions among regulator genes that were identified by the Bayesian network and the known biological interconnectedness between downstream mediator and upstream regulator genes, 2 linear models were developed to describe the relationship among the regulator genes and between the regulator and mediator genes.
Comparative Gene Expression Data From Lower Extremity Angioplasty and Trauma Patient Cohorts
Gene expression data from 2 of our group's previously published parallel studies on patients with lower extremity angioplasty and blunt trauma were compared with results of the current study. These data were collected from circulating monocytes and processed and analyzed using technique analogous to those used in this study. Data from 14 patients undergoing lower extremity angioplasty/stenting (8 success and 6 failure) 17 and 126 patients having blunt traumatic injury (63 complicated and 63 uncomplicated recovery course) 18 were included. Criteria for angioplasty success and failure were similar to those used in this study. Patients with trauma who recovered in <5 days were considered uncomplicated; a recovery time >14 days, no recovery by 28 days, or death was categorized as complicated.
RESULTS

Patient Demographics and Procedural Details
Data collected from 48 patients undergoing autogenous infrainguinal vein bypass grafting for critical limb ischemia or disabling claudication were included in the final analysis. Thirteen grafts (27%) failed within the first postoperative year ( Figure I in the Data Supplement). Mean age at operation was 64.3 years, and all but 2 patients were men. A history of coronary artery disease, diabetes mellitus, hypertension, hyperlipidemia, and current or prior smoking was common, as was usage of aspirin and lipidlower statin agents (Table I in the Data Supplement). The mean preoperative ankle-brachial index was 0.39. In all but 3 patients, surgical bypass was performed to resolve critical limb ischemia. The common femoral artery was the most common inflow vessel (77%) and the tibial vessels the most common distal target (71%). The preferred conduit, a single segment of nonreversed greater saphenous vein, was used in the majority of cases (63%; Table II in the Data Supplement). With the exception of hyperlipidemia (P=0.048), no preoperative comorbidity, medication, or operative detail was present at a significantly greater frequency in either of the outcome groups.
Isolated Monocyte Phenotypes
Classical monocytes (CD14 + CD16 − ) made up 82% to 87% of the total monocyte pool in patients whose grafts remained patent, whereas they comprised 74% to 82% of the pool in failed grafts (Table III in the Data Supplement). Independent t tests at each time point showed no differences in the percentages of classical monocytes between successful and failed grafts. Similarly, the time-dependent trajectories (time×outcome effect) of classical monocyte proportions were not significantly different between the 2 groups.
Identification of a Temporally Dynamic Gene Subset
Mixed-effects modeling demonstrated time rather than outcome to be the dominant influence on gene expression. Expression levels of 1870 of the 20 213 genes represented on the microarray chip changed significantly over time (false discovery rate<0.001), yet no single gene showed a significant difference in expression between outcome groups. Principal component analysis revealed that the greatest perturbation in gene expression levels occurred within the first postoperative day and corroborated the mixed model's results by showing no separation between the outcome groups ( Figure 1A) . Similarly, an unsupervised heatmap of the 1870 genes at each patient×time point showed rough clustering by time, notably at day 1, but no clustering by outcome ( Figure II in the Data Supplement). A more quantitative evaluation of these relationships demonstrated minor separation of successful and failed graft distance from reference expression profiles at days 7 and 28, which failed to reach statistical significance (P=0.98; Figure 1B ).
Gene Cluster Generation and Selection
Although mixed-effects modeling identified no single gene with outcome-dependent differential expression, we suspected that there might be groups of genes that, when considered in aggregate, might show an expression difference between the outcome groups. 19 To test this hypothesis, a custom clustering algorithm was applied to the 1870 time-dependent genes and divided the genes into 50 unique clusters, each with its own time-dependent signature pattern. 15 Each gene was assigned to only 1 cluster (Figure 2 ). These clusters were then subjected to a stringent selection process intended to identify those clusters that are most likely to be associated with vein graft outcome. Only 3 of the 50 clusters satisfied all 4 of the following selection criteria: (1) significant outcome effect identified by the clustering algorithm, P<0.001; (2) significant outcome effect identified by traditional ANOVA, P<0.05; (3) normalized Cohen d effect size at any time point between outcome groups >0.5; and (4) >1.4-fold or <0.7-fold change in mean expression between any 2 time points. These 4 criteria were used to ensure that gene expression within each selected cluster was substantially dynamic over time and met a generally accepted threshold for differential expression between outcome groups (Figure 3 ; Figure III in the Data Supplement). Common to all 64 genes within the 3 clusters was early augmentation of expression at day 1 with eventual return to baseline toward the end of the postoperative month. This heightened early response was significantly more pronounced in those grafts that progressed to failure (mean fold change from baseline, 2.17 versus 1.76; P<0.001; Figure 4A) . Furthermore, failed grafts demonstrated a more rapid decrease in gene expression levels over the postoperative month (decay time constant, 178 versus 207 seconds; P<0.001). Enriched canonical pathways for this 64-gene set, identified with the Ingenuity Pathway Analysis software, included IL (interleukin)-10 and IL-6 signaling, glycogen degradation, STAT3 (signal transducer and activator of transcription 3) signaling, and granulocyte adhesion and diapedesis ( Figure 4B ).
Comparison to the Monocyte Response After Peripheral Angioplasty and Major Trauma
Using datasets available through 2 previous clinical studies performed by our group, a comparison of the aggregate monocyte response pattern for this set of 64 genes was performed for vein bypass grafting, peripheral angioplasty, and major trauma. Significant timedependent variation in gene expression was observed in all 3 clinical scenarios, with major trauma demonstrating the most robust day-1 deviation from baseline among these groups ( Figure 5A ). Consistent with the less invasive nature of the procedure, a more modest response after angioplasty was observed.
Examining the relationship of these 64 genes to patient outcome (ie, vascular intervention patency or trauma recovery course) demonstrated significant differences in both day 1 and day 7 expression for complicated versus uncomplicated clinical recovery after trauma ( Figure 5B ). In contrast, limited separation of aggregate gene expression as a function of angioplasty or bypass outcomes was observed. Examination of these data sets using a distance from reference plot corroborated these findings ( Figure 5C ).
Comparison to Weighted Gene Co-Expression Network Analysis
To compare the robustness of our clustering approach to other networking algorithms, the monocyte mRNA data set was analyzed using the WGCNA (Weighted Gene Co-Expression Network Analysis) methodology. Technical aspects of the analysis and results are in the Results section. Of the 3 postoperative time points, common expression patterns associated with vein graft outcome were identified only at day 7, where 4 of the 19 clusters reached a significance threshold of P<0.05. Unlike our current data mining technique, analysis of these genes within Ingenuity Pathway Analysis failed to identify any upstream regulators, implying limited biological commonality among these genes. No gene was common between the set of 64 genes derived from our clustering algorithm and that identified by WGC-NA. One key difference between the 2 methods is the importance of gene dynamics. Although our clustering algorithm implicitly integrates changes in gene expression over time, WGCNA uses a time-static approach.
Identification of Upstream Regulatory Elements
Ingenuity Pathway Analysis of this gene set identified 8 upstream elements as important regulators of the larg- er set of 64 genes ( Figure 6 ). Seven of these genes (IL-6, STAT3, AGT, CSF3, DICER1, HGF, and VEGF-A) were common among both success and failure groups, at days 1 and 7. However, by day 28, only IL-6 and STAT3 were relevant regulators for those grafts that failed, and AGT (angiotensinogen), DICER1 (endoribonuclease dicer), and an eighth gene (MYD88) were dominant regulators for successful grafts. Ontology analysis revealed a set of highly interconnected regulatory genes with central roles in inflammation, cell growth, angiogenesis, and neutrophil proliferation.
Although the expression levels of these upstream regulatory genes within the monocyte were dynamic over time and varied between outcome groups (FigFigure 4 . Expression profiles of the final 64 genes contained in 3 clusters. A, All genes showed early augmentation of expression at day 1 followed by eventual return toward baseline during the course of the month. This heightened early response was significantly more pronounced in those grafts that progressed to failure (mean fold change from baseline, 2. Table IV in the Data Supplement). We hypothesized that these regulators form an integrated network that acts in concert to modulate the expression of downstream meditator genes.
Alteration of Predicted Graft Outcome Through Manipulation of Regulator Genes
Bayesian network analysis among the 8 upstream regulator genes identified 4 interactions to which the linear regression model for predicting regulator gene expression changes were constrained ( Figure 7B ). Silencing regulator genes individually within our model yielded a wide range of predicted aggregate effects on the downstream mediator genes. In general, early regulator gene inhibition tended to favor movement toward a more successful phenotype.
Interestingly, the silencing of some regulators had varying effects at different time points, likely reflecting the time-dependent nature of the processes that govern graft remodeling. Silencing of either the transcription factor STAT3 or the signal transduction molecule MYD88 (myeloid differentiation primary response 88) A, Mixed-effects modeling identified DICER1 (endoribonuclease dicer), HGF (hepatocyte growth factor), and STAT3 (signal transducer and activator of transcription 3) expression as changing significantly over time (P=0.01, P=<0.01, and P=<0.01). CSF3 (colonystimulating factor 3) expression demonstrated significantly different time-dependent trajectories between the outcome groups (P=0.05). The remaining genes showed temporally dynamic expression that failed to reach statistical significance. B, Gene expression data for the 8 upstream regulator genes were discretized as 1 (downregulation) or 2 (upregulation) by comparing with the baseline expression level. A Bayesian network was created to describe the relationships among the genes. This analysis identified 4 interactions to which the linear regression models for predicting regulator gene expression changes were constrained. AGT indicates angiotensinogen; IL6, interleukin-6; MYD88, myeloid differentiation primary response 88; and VEGFA, vascular endothelial growth factor A.
was predicted to have the most beneficial influence, modulating downstream mediator expression strongly toward success throughout the postoperative month. In contrast, removal of HGF was associated with a negative effect on graft phenotype, which escalated throughout the postoperative month. Other regulators, such as AGT or IL-6, demonstrated a mixed picture, where inhibition at day 1 shifted gene expression strongly toward success, but silencing at subsequent time points had minimal effect on the predicted phenotype ( Figure 8A ; Figures IV and V in the Data Supplement).
Pairs of regulators were inhibited simultaneously to explore the possibility of synergistic effects. However, in every case, the aggregate effect of simultaneous knockout was either similar or identical to the effect achieved by simply summing the individual effects ( Figure 8B ).
DISCUSSION
The linkage between chronic activation of the immune system and the severity of vascular disease has been well established. 17, 20 General markers of inflammation, such as CRP and IL-6, have been correlated with advanced atherosclerosis and an elevated risk of morbidity and mortality. 18 Although humoral immunity has a long recognized role in the initiation and progression of atherosclerosis, 21 the importance of cell-mediated immunity in physiological and pathophysiologic vascular adaptation has been increasingly recognized. Specifically, monocyte infiltration and macrophage activation are critical and necessary components to homeostatic arterial remodeling triggered by hemodynamic stress. 22, 23 These concepts have been extended to vein graft biology and the potential mechanisms of failure. Enhanced systemic inflammation, as assessed by CRP levels, has been associated with impaired remodeling and increased failure in human vein grafts. 24, 25 Further mechanistic investigation in animal models has identified enhanced monocyte binding and macrophage accumulation as importance drivers of accelerated intimal growth, 9, 26 particularly in areas exposed to reduced shear stress. 27 Subsequent studies have provided granularity to these findings, identifying early monocyte recruitment and activation by necrotic smooth muscle cells, injured during implantation, as fundamental components of pathological vein graft remodeling. [10] [11] [12] 28 The potential importance of this mechanism in human vein graft disease is supported by the observation that enhanced monocyte adhesion immediately after surgical manipulation is associated with subsequent graft failure. [29] [30] [31] However, a comprehensive understanding of the early monocyte response to vein graft implantation and the genomic modulation that drive grafts toward either patency or stenosis and failure is lacking. Hence, we have taken a top-down approach by using high-throughput genomics to examine the dynamic signatures within the monocyte and then, in a systematic and logical fashion, culling these ≈20 000 genes to a set of 8, therapeutically modifiable genes that seem integral to determining a monocyte response phenotype associated with graft outcome.
This relationship between the systemic inflammatory environment and local graft remodeling begs the question of causality. We think that the circulating monocyte acts at the site of implantation to influence vein graft biology and, ultimately, clinical phenotype. The reverse scenario, in which the monocyte is simply a marker of graft health is less plausible, given the existing data derived from animals showing monocytes and macrophages as drivers of intimal proliferation. 9, 26 Our finding that surgical bypass grafting elicits a significant perturbation in monocyte gene expression, as evidenced by the identification of 1870 genes whose expression changed significantly throughout the first postoperative month, is consistent with previously published studies. In cells isolated from the outer wall of human saphenous vein grafts, Kenagy recently showed that 5% of the genes significantly altered their expression after stimulation with either Platelet Derived Growth Factor or serum. 32 Similar changes have been observed in other vascular pathologies, where blood leukocytes isolated from patients undergoing open thoracoabdominal aneurysm repair showed time-dependent changes of 146 genes within the first 24 hours alone. 33 The early (day 1) augmentation of monocyte gene expression that was seen uniformly among our group of 64 genes is consistent with existing data, indicating that postoperative inflammatory processes reach a zenith within the first several postoperative days. 1 Our finding that expression levels of these same 64 genes after trauma exhibit a similar pattern suggests that this gene group may be fundamentally important in the immune response to injury. Genomic analysis of endothelial and smooth muscle cells derived from canine vein bypass grafts showed a similar temporal pattern of expression, with the maximal number of differentially expressed genes seen at 12 hours and 7 days postoperation. 1 The striking pattern of increased monocyte gene expression among failed grafts compared with patent grafts at day 1 is congruent with the general observation that increased inflammation is associated with vein graft failure. 34 Our approach to identifying the discrete set of biologically important genes from among the larger pool relies critically on the idea that it is likely groups of genes acting in concert, rather than lone genes in isolation, which drive the metabolic processes governing graft remodeling. The creation of our custom clustering algorithm to group together genes with similar expression profiles over time was borne from this concept. 15 Kenagy et al, also appreciating the importance of considering genes in groups rather than as independent entities, used WGCNA in an attempt to identify the core genes that may play critical roles in vein graft failure. This technique, like ours, assumes the fundamental concept that genes with similar expression likely act in a coordinated manner. As in our study, their genomic analysis of outer wall cells isolated from human vein grafts demonstrated that although no single gene was differentially expressed between successful and failed grafts, 2 separate groups comprising a total of 42 genes were associated with graft outcome. 32 The identification of 8 key regulatory genes through pathway analysis is an important contribution of the current study, proposing these upstream regulators as prime targets for possible intervention to modify vein graft outcome. Among our set of 8 genes, several have known roles in vascular pathophysiology. Among them, VEGF (vascular endothelial growth factor) is well-established as a principal regulator of angiogenesis. 35 Our Bayesian network analysis identified DICER1 as the central node among the 8 regulator genes, implying its role as a governor of this small gene network. DICER1 encodes the enzyme Dicer, which plays a critical role in RNA silencing through the creation of small interfering RNA and microRNA. A substantial amount of research has identified associations between Dicer and endothelial atherosclerosis by its ability to generate microRNA that regulates processes such as macrophage activation, inflammation, and vascular smooth muscle cell phenotype.
36-39 Our model's identification of Dicer as a central network regulator supports the notion that microRNA might play important roles in vascular remodeling within the context of our study.
The transcription factor STAT3 plays a role in converting vascular smooth muscle cells from a quiescent state to a synthetic state. 40 When transfected into these cells, STAT3-targeted small interfering RNA inhibition reduced their proliferation in vitro and also led to decreased neointimal thickness in rat jugular-carotid grafts. 41 Further work confirmed this observation, where inhibition of STAT3 activation by SOCS3 (suppressor of cytokine signaling 3) overexpression attenuated smooth muscle cell growth and migration. 42 Our model identified STAT3 silencing as one of the strongest pushes toward graft success and thus corroborates, for the first time with human data, the clinically beneficial effects of STAT3 inhibition that previously have been demonstrated solely in animal studies.
Our analysis revealed a highly interconnected set of regulator genes with variable early response patterns. Not surprisingly, the model identified several regulator genes, most notably HGF, whose in silico inhibition migrated the predicted graft phenotype toward a failed outcome. HGF's positive role in vein graft remodeling was dem-onstrated in rabbit vein grafts, which showed reduced wall thickening among those overexpressing lentiviraldelivered HGF. 43 In vivo delivery of an engineered HGF fragment within an extracellular matrix-derived hydrogel improved left ventricular remodeling and increased arteriole density in a rat model of myocardial infarction. 44 Its use has already expanded to humans, as a phase I clinical trial demonstrated the safety of intracoronary administration of adenoviral-mediated HGF to patients with severe coronary artery disease. 45 Limitations of our study are largely related to certain assumptions that are implicit in the analysis. Among the most critical of these assumptions are that the most biologically important genes act in concert with similar expression profiles, that the biological interactions among the regulatory elements are properly characterized by the Bayesian network, and that the final graft phenotype can be adequately predicted by a linear, combinatorial analysis. Our study also lacked an independent validation data set to confirm our findings. Although not definitive, the observation that the most critical regulators have known roles in influencing the activation state of inflammatory cells lends support to our conclusions.
Statistical modeling is the backbone of our analysis. The collective use of mixed-effects modeling to identify temporally dynamic genes, a gene clustering algorithm to group together those that behave similarly, a Bayesian network to identify gene regulatory relationships and linear regression modeling to predict the vein graft phenotypic effects of regulator gene manipulations is a novel approach that provides tremendous insight into the monocyte genomic influence on vein graft outcome in human patients. Importantly, this approach has given us, through statistical inference, results that would otherwise have been logistically unobtainable through conventional experimentation on humans. This same process can be applied to numerous other analyses in which one needs to distill large amounts of gene expression data down to only that tiny subset, which is of greatest interest.
